Akoya Biosciences, Inc.
AKYA
$1.16
$0.021.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.32% | -19.42% | -25.39% | -1.52% | -14.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.32% | -19.42% | -25.39% | -1.52% | -14.29% |
| Cost of Revenue | -32.12% | -29.51% | -28.66% | -14.27% | 9.37% |
| Gross Profit | 17.81% | -13.42% | -23.25% | 10.48% | -31.84% |
| SG&A Expenses | -11.49% | -21.88% | -27.55% | -20.13% | -14.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.49% | -23.33% | -28.13% | -19.12% | -8.37% |
| Operating Income | 22.14% | 35.07% | 34.25% | 41.24% | 0.99% |
| Income Before Tax | 33.38% | 24.18% | 18.70% | 36.96% | -24.76% |
| Income Tax Expenses | -23.81% | 63.64% | 193.33% | 161.11% | 117.24% |
| Earnings from Continuing Operations | 33.35% | 24.10% | 18.45% | 36.79% | -24.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.35% | 24.10% | 18.45% | 36.79% | -24.90% |
| EBIT | 22.14% | 35.07% | 34.25% | 41.24% | 0.99% |
| EBITDA | 23.48% | 42.29% | 35.76% | 45.44% | 0.67% |
| EPS Basic | 33.98% | 24.82% | 19.30% | 48.02% | 2.69% |
| Normalized Basic EPS | 18.89% | 4.15% | 25.17% | 47.16% | 20.70% |
| EPS Diluted | 33.98% | 24.82% | 19.30% | 48.02% | 2.69% |
| Normalized Diluted EPS | 18.89% | 4.15% | 25.17% | 47.16% | 20.70% |
| Average Basic Shares Outstanding | 0.97% | 0.96% | 1.08% | 21.61% | 28.34% |
| Average Diluted Shares Outstanding | 0.97% | 0.96% | 1.08% | 21.61% | 28.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |